Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside

<p>1. Novel targets for parkinsonism-depression comorbidity<br>Yousef Tizabi, Bruk Getachew, Antonei B. Csoka, Kebreten F. Manaye and Robert L. Copeland<br>2. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings<br>Sonja Elsaid, Stefan Kloiber and Bernard Le Foll<br>3. Stress, psychiatric disorders, molecular targets, and more<br>Fatin Atrooz, Hesong Liu and Samina Salim<br>4. Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's disease<br>Ramsha Shams, Naren L. Banik and Azizul Haque<br>5. Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders<br>Patrick J. Ronan, Sarah A. Flynn and Thomas P. Beresford<br>6. Emerging evidence for the role of pituitary adenylate cyclase-activating peptide in neuropsychiatric disorders<br>Kabirullah Lutfy and Shankar Gollapudi<br>7. Glial mechanisms underlying major depressive disorder: Potential therapeutic opportunities<br>Shafiqur Rahman and Sami Alzarea<br>8. Its complicated: The relationship between alcohol and microglia in the search for novel pharmacotherapeutic targets for alcohol use disorders<br>Jennifer K. Melbourne, K. Ryan Thompson, Hui Peng and Kimberly Nixon<br>9. Microglia as possible therapeutic targets for autism spectrum disorders<br>Megumi Andoh, Yuji Ikegaya and Ryuta Koyama</p>